Clinical Trial Update: Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tivantinib for recurrent or metastatic breast cancer has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Status: COMPLETED | Results posted: 2016-03-21